Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy


Cite item

Full Text

Abstract

Cardiovascular diseases (CVD) and cancers are the leaders in their prevalence and the major causes of death in economically developed countries, determining their high sociomedical significance in society. Improvement of methods for the early diagnosis and treatment of cancers has contributed to increases in relapse-free survival and life expectancy in these patients. At the same time, the new problems have emerged particularly in the development of various cardiovascular events/diseases when treating cancer, which may predict worse prognosis in patients and be an independent cause of death. To search for new markers of cardiotoxicity at early stages and to develop effective methods for the prevention and personalized treatment of cancer and CVD are the problems that can be solved only by joint efforts of cardiologists and oncologists.

References

  1. Информационный бюллетень №297 СМИ ВОЗ Февраль 2012 г. Russian (Informacionnyj bjulleten’ N297 SMI VOZ Fevral’ 2012 g.).
  2. Hong RA, Limura T, Sumida KN, Eager RM. Cardio-Oncology/Onco-Cardiology. Clin Cardiol. 2010;33:733-737.
  3. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-2247.
  4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
  5. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20: 1215-1221.
  6. Giordano SH, Booser DJ, Murray JL et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three- hour- infusion paclitaxel in patients with metastatic breast cancer. Clin CancerRes. 2002;8:3360-3368.
  7. van Dalen EC, Caron HN, Dickinson HO et al. Cardioprotective interventions for cancer patients receiving anthracyclines.Cochrane Database Syst Rev 2005; CD003917. http://www.cochrane.org. Accessed April 16, 2008.
  8. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
  9. van Dalen EC, van der Pal HJH, Bakker PJM et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer. 2004;40:643-652.
  10. Guglin M, Hartlage G, Reynolds C et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651-657.
  11. Ewer MS, Vooletich MT, Durand J et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-7826.
  12. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679-686.
  13. Atallah E, Durand J, Kantarjian H et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.
  14. Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500-2508.
  15. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370: 2011-2019.
  16. Kantarjian H, Cortes J, Kim D et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113: 6322-6329.
  17. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.
  18. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991;99:557-561.
  19. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
  20. Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13:484-485.
  21. Ang C, Kornbluth M, Thirlwell MP et al. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol. 2010;17:59-63.
  22. Tsibiribi P, Descotes J, Lombard-Bohas C et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. BullCancer. 2006;93:E27-E30.
  23. Schwarzer S, Eber B, Greinix H et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12:748-750.
  24. Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J. 1996;60:185-188.
  25. Swerdlow AJ, Higgins CD, Smith P et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206-214.
  26. Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70: 690-691.
  27. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99: 1232-1239.
  28. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
  29. Arbuck SG, Strauss H, Rowinsky E et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;15:117-130.
  30. Lee RE, Lotze MT, Skibber JM et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7-20.
  31. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:852-3860.
  32. McLellan RA, Drobitch RK, Monshouwer M et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos. 1996;24:1134-1138.
  33. Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol. 1999;19:491-510.
  34. Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res. 1995;19:141-144.
  35. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.
  36. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
  37. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25: 3109-3115.
  38. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session, 2003.
  39. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol and cardiovascular disease. Hypertension. 2000;36:912-916.
  40. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. AnnIntern Med. 2003;139:761-776.
  41. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3d ed. Dallas, TX: Lippincott Williams & Wilkins. 2003:516-519.
  42. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766-773.
  43. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150: 977-982.
  44. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur JNucl Med. 1997;24:286-292.
  45. Cuzick J, Stewart H, Rutqvist L et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447-453.
  46. Hooning MJ, Botma A, Aleman BMP et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365-375.
  47. Dolci A, Dominici R, Cardinale D et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688-695.
  48. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J AmColl Cardiol. 2000;36(2):517-522.
  49. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-2754.
  50. Cаржевский В.О., Колесникова Д.С., Мельниченко В.Я., Тюрин В.П. Кардиотоксичность высокодозной химиотерапии и аутологичной трансплантации костного мозга при онкогематологических заболеваниях. Клиническая онкогематология. 2013;6(3):324-332.
  51. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82(4):218-222.
  52. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-2481.
  53. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136(2):362-363.
  54. Nousiainen T, Jantunen E, Vanninen E et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998;61(5):347-353.
  55. Horacek JM, Pudil R, Tichy M et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol. 2007;29(3):243-247.
  56. Snowden JA, Hill GR, Hunt P et al. Assessment of cardiotoxicity during hematopoietic cell transplantation with plasma brain natriuretic peptide. Bone MarrowTransplant. 2000;26(3):309-313.
  57. Zver S, Zadnik V, Bunc M et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007;85(5):408-414.
  58. Munker R, Lazarus HM, Atkinson K. The BMT Data Book. 2nd ed. Cambridge: Cambridge University Press; 2009:237.
  59. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91-98.
  60. Styler MJ, Topolsky DL, Crilley PA et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant. 1992;10(5):435-438.
  61. Chung T, Lim WC, Sy R et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart. 2008;94(7):911-918.
  62. Pihkala J, Saarinen UM, Lundstrom U et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant. 1994;13(2):149-155.
  63. Zver S, Zadnik V, Cernelc P et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int JHematol. 2008;88(2):227-236.
  64. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). M.; 2010:428.
  65. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
  66. Ganz WI, Sridhar KS, Ganz SS et al. Review of tests for mon- itoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-470.
  67. van Dalen EC, van den Brug M, Caron HN et al. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006;42:3199-3205.
  68. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89(5 pt 1):942-949.
  69. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24: 4107-4115.
  70. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228-234.
  71. Donmez A, Zoghi M, Cagirgan S et al. The effect of hematopoietic progenitor cells’ temperature on cardiac arrhythmias in patients given peripheral blood progenitor cells. Transfus Apher Sci. 2006;34(3):245-251.
  72. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492-2498.
  73. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22(5):820-828.
  74. Lipshultz SE, Lipsitz SR, Sallan SE et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517-4522.
  75. Kakavas PW, Ghalie R, Parrillo JE et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant. 1995;15(6):859-861.
  76. Bosch X, Esteve J, Sitges M et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17(8):643-648.
  77. De Angelis A, Piegari E, Cappetta D et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-292.

Copyright (c) 2015 Chazova I.E., Oshchepkova E.V., Kantorova A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies